Introduction
Previous studies have shown an association between psychological changes and temporomandibular joint dysfunction (TMD) (1,2). It has been estimated that approximately 20% to 30% of the adult population will experience TMD in their lifetime (3), and pain associated with TMD may occur in about 70% of patients diagnosed with these disorders (4). Pain is an unpleasant experience that reflects on interpersonal relationship. It is considered an aversive stimulus able to alter the patient's level of anxiety. Anxiety is an emotional state subjectively considered unpleasant or threatening, including symptoms such as alterations in the mood and cognition, mostly followed by behavioral and physiological changes, such as palpitation, and sudoresis (5). Anxiety can become pathological when a response to the stimulus becomes exaggerated and irritating interfering in the quality of life (5). Considering that thoughts and feelings related to pain suffering may play an important role in dental distress similarly to the pain in other parts of the body, anxiety is probably the most important of the non-sensory components of dental pain (2). In the last years different studies have analyzed the possible role of anxiety in pain responses (1), but the influence of pain, mainly orofacial pain, on anxiety levels is still unknown. To measure pain and anxiety in human beings is very complex. Animal models may help to investigate the mechanisms involved in normal and pathological behavior. The formalin (FT) and the elevated plus-maze (EPM) tests are useful tools to study pain and anxiety, respectively. The FT is widely used as a model for subacute tissue injuryinduced pain in rodents (6). The formalin injection into the paw elicits a biphasic behavioral response in rats (7, 8) . This test is considered a model of inflammatory tonic pain and it is sensitive to many classes of analgesic drugs (9). An adaptation of this test for assessing pain and analgesia in the orofacial region of the rat was introduced by Clavelou et al. (1995) (10) . The formalin injection in the upper lip induced a nociceptive behavioral response in the animal characterized by rubbing the formalin-injected upper lip whit the ipsilateral fore or hindpaw. In 2001, Roveroni et al. (11) developed a behavioral model of orofacial pain in deep tissues of rats using formalin injection in the TMJ region. The formalin administration in the TMJ causes behavioral responses in rats characterized by moving the mandible, rubbing the orofacial region and flinching the head quickly. The elevated plus maze test is one of the most widely used models in animals, in contemporary preclinical research on anxiolytic drugs and neurobiological mechanisms of anxiety (12, 13 where the arms crossed. The whole apparatus was elevated 50 cm above the floor. To prevent the rats from falling down, a rim of Plexiglas ® (1 cm high) was made to surround the perimeter of the open arms. The experimental sessions were recorded by a vertically mounted video camera, linked to a monitor and a VCR in an adjacent room. Afterwards, the videotapes were analyzed by three calibrated observers who were blinded to the treatment conditions. The solutions administered in the experiment were: Halothane ® (Cristália, São Paulo, SP, Brazil); Diazepam ® (Roche, Jacarepaguá, RJ, Brazil) diluted in propilenoglicol 40% (01 mg/kg) (16); 1.0% Formalin prepared from 37% stock formaldehyde (Sigma-F-1635, Sigma Chemical Co ® ; St Louis, MO, USA) further diluted in 0.9% saline; Blue Evans 1% (Sigma Chemical Co ® ; St Louis, MO, USA) dissolved in physiological saline (30 mg/kg body weight). On the experiment day, the animals were taken to the test laboratory room, at least 30 minutes before treatment, and anaesthetized with halothane for 40 s before any procedure. To evaluate the effect of superficial (lip) and deep (TMJ) orofacial pain on the anxiety level, the rats were randomly allocated to the experimental groups shown in Table 1 . Gentle aspiration ruled out any intravascular placement, after administration of 50 µL of the experimental solution.
For the lip and TMJ injection a 30-gauge needle was used associated with a 0.5-in needle coupled to a Hamilton microsyringe through a polietylene canule. After the EPM test, the formalin/saline TMJ group received intracardiac injection of Evans' blue dye to confirm if the formalin administration was adequate.
To validate the behavioral result and evaluate the γ-Aminobutyric acid (GABA) role in the alteration observed in experiment 1, other experiments were performed (Table 2) . Animals were anesthetized with halothane prior to intraperitoneal drug administration, 30 min before formalin/ vehicle injection in the lip or TMJ. After treatment, the rats were placed in an individual cage and taken to the behavioral room for a 30-min waiting period before the EPM-test. For the behavioral test each rat was placed in the central square facing an enclosed arm, and allowed to freely explore the EPM for 5 min Data were statistically analyzed by using ANOVA followed by Tukey's tests at the significance level of 5%. The softwares used for statistical calculations were Minitab, Estat and Sisvar (Globaltehc, Santo Agostinho, BA, Brazil).
Results
For the effect of formalin injection in the lip and in the TMJ region groups on anxiety levels, local factors and treatment of anxiety and locomotor activity in animals submitted to the EPM test were significant, but with no interaction between these two factors. For local factor, no statistically significant difference was found between anxiety and locomotor activity when formalin was injected in the region of TMJ or lip (P<0.05) ( Table 3 and Fig. 1 ). Regarding the treatment factor, formalin 1% administration increased (P<0.05) anxiety level significantly as assessed by the %TSOA and the %EOA (Table 3 and Fig. 1 ). 
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As estimated by NECA, formalin did not alter the locomotor activity of animals tested with the LCE in comparison with the rats treated with saline control (Fig. 1) . The intraperitoneal administration of Diazepam ® (1.0 mg/ kg body weight) significantly reduced (P<0.05) the anxietyinduced nociception response by formalin 1% injection in both lip and TMJ, as seen mainly by %TSOA (Fig. 2 B) . However, there was not effect on the locomotor activity as measured by % EOA% and NECA (Table 4 and Fig. 2 ).
Discussion
Orofacial pain and anxiety seem to be related (17). As the measurement of pain and anxiety in human beings is complex, animal models are useful to allow a better control of the experimental variables. The pain, similarly to different aversive stimuli, is able to alter the anxiety level of animals (15). To study orofacial pain in deep tissue many substances has been used such as mustard oil, glutamate, carrageenin and formaline (18). The FT is a reliable method for assessing pain in the trigeminal region (10, 11, 15) . The EPM-test is an experimental model in laboratory animals to measure anxiety levels (12), where the percentage of time spent in the open arms is inversely related to anxiety levels (12,13). Since the measurement of anxiety may be influenced by locomotor activity, this factor was assessed by recording the absolute number of closed-arm entries, which is considered to be an indicator of general motor activity (12). The lower percentage of time spent in the open arms by the animals that received formalin injection in the lip or in the TMJ regions compared with the control indicated that pain increased the level of anxiety. These findings suggest that the anxiogenic effect, after formalin injections, was related with the stimulated anxiety and not to the locomotor activity of the rats. For pain induction by injecting algesic agents in the rats' periarticular regions, the animals were first anesthetized by halothane inhalation. Although pre-administration of halothane can reduce the paw edema induced by formalin injection to a limited extent, it does not produce an inhibitory effect on the nociceptive behavioral response shown by the rats that were submitted to the formalin test (14). This ensured that there was no interference of halothane in the induction of formalin nociceptive stimuli. Whereas there was the deposition of a certain volume of solution in the area injected (lip or TMJ), the pressure caused by this volume may have been an important factor in the activation of local nociceptors response, likely to cause pain and alter the anxiety level. However, there was no statistically significant difference neither in the percentage of time spent inside or the number of entries in the open arms, or even in the number of entries in the closed arms of the control group (GC) compared with the group that received saline injection in the lip or TMJ area. Therefore, these findings suggest that the saline injection in the orofacial region did not change the anxiety level nor the locomotor activity of rats tested with the EPM. A reduction in the percentage of time spent inside and in the number of entries in the open arms in the EPM test induced by formalin injection in the lip and in the TMJ areas, Table 4 . Comparison of % TSOA, % EOA and NECA between control and experimental groups submitted to EPM test after injection of 1% formalin in the orofacial area. Mean (± standard error of the mean). compared with their controls, indicates that this procedure has an anxiogenic effect. When analyzing the number of entries in the closed arms, there was no significant difference between the groups, indicating that although the pain induced by formalin injection increases the anxiety levels, this procedure does not change the locomotor activity of the animals as previously reported by Roveroni et al. (11) . Although there are differences between the pain from superficial and deep orofacial tissues (20), which could reflect changes in the anxiety levels, the results of the present study showed that when the lip/formalin and TMJ/formalin groups were compared, the percentage of time spent in the open arms was not different between groups. This finding suggests that the injection of 1% formalin in the orofacial region produces a nociceptive stimulus that induces anxiety in a similar degree, regardless of the area in which it was injected. Probably, the mechanism of action by which formalin is able to alter the levels of anxiety involves the release of endogenous serotonin, which occurred during the phase 2 of the formalin test ( (Table 4) shows that the intraperitoneal anxiolytic administration reduced the anxiety level caused by the formalin injections in both areas, compared with their respective controls. This demonstrated that the behavioral changes as observed during the EPM tests are related to the alterations of anxiety levels as a result of the formalin treatment. The fact that Diazepam ® reduced the anxiety induced by the formalin injection in the orofacial region does not exclude the possibility that the anxiolytic could be acting directly on the nociceptive system, which would result in a change in the EPM test results. No other studies have assessed the antinociceptive effect of Diazepam ® in the formalin test in the orofacial region. Based on these results, one accepts the hypothesis that nociceptive response in rats' orofacial area induced by 1% formalin injection in the lip or the TMJ regions can influence anxiety levels. Although our results show that the formalin nociception-induced in the orofacial region can increase anxiety levels in this animal model, it is not possible to conclude that anxiety could interfere with nociception. We believe that due to the fact that there are several nerve pathways involved in both pain and anxiety, these two factors can overlap and mask the results. Animal models allow the investigation of nociception but not of pain perception. Although the most important point to be examined is the perception of pain, it depends on a number of emotional, cultural and social factors with individual responses. This is why studies in humans are the ultimate standard to unravel the complex relationship between orofacial pain and anxiety. Considering the relation between psychological factors and the incidence of temporomandibular disorders, anxiety is the major factor of pain perception, and individuals that show high anxiety levels in their daily behavior are more reactive to pain than those who are less anxious (21). However, the results of the present study showed that pain can also increase anxiety levels. Therefore, it is necessary that dentists acknowledge that orofacial pain, regardless of its origin, can alter patients' levels of anxiety, consequently intensifying the distress and inducing a vicious cycle in which pain and anxiety are exacerbated, which may influence the outcome of any dental treatment. This ratifies the need for the interdisciplinary approach of a health team to treat orofacial pain cases.
Conclusions
The results suggest that orofacial nociceptive response induced by 1% formaline injection in superficial (lip) and deep (TMJ) region of rats increases the anxiety level without interfering in the locomotor activity. Diazepam ® reduces the anxiety caused by orofacial pain in both superficial and deep tissue.
